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Background: Literature has shown that dissemination of guidelines alone is insufficient to ensure that guideline
recommendations are incorporated into every day clinical practice.
Methods: We aimed to investigate the gaps between guideline recommendations and clinical practice in the
management of young people with depression by undertaking an audit of medical files in a catchment area public
mental health service for 15 to 25 year olds in Melbourne, Australia.
Results: The results showed that the assessment and recording of depression severity to ensure appropriate
treatment planning was not systematic nor consistent; that the majority of young people (74.5%) were prescribed
an antidepressant before an adequate trial of psychotherapy was undertaken and that less than 50% were
monitored for depression symptom improvement and antidepressant treatment emergent suicide related
behaviours (35% and 30% respectively). Encouragingly 92% of first line prescriptions for those aged 18 years or
under who were previously antidepressant-naïve was for fluoxetine as recommended.
Conclusions: This research has highlighted the need for targeted strategies to ensure effective implementation.
These strategies might include practice system tools that allow for systematic monitoring of depression symptoms
and adverse side effects, particularly suicide related behaviours. Additionally, youth specific psychotherapy that
incorporates the most effective components for this age group, delivered in a youth friendly way would likely aid
effective implementation of guideline recommendations for engagement in an adequate trial of psychotherapy
before medication is initiated.Background
A range of guidelines exist for depression in young people,
including US guidelines for primary care [1] and the prac-
tice parameters of the American Academy of Child and
Adolescent Psychiatry (AACAP) [2] UK guidelines [3] and
most recently an Australian guideline [4]. Key recommen-
dations are consistent across these, advocating sequencing
of interventions from low intensity for mild presentations
to more intensive psychotherapy for moderate to severe
presentations, with medication (fluoxetine first line) con-
sidered if necessary; and in this case close monitoring,* Correspondence: shetrick@unimelb.edu.au
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reproduction in any medium, provided the orparticularly for emergent suicidality. However, it is widely
recognized that implementation of guideline recommen-
dations into every day clinical practice is far from univer-
sal [5] due to barriers at levels: 1. the individual clinician
(e.g. knowledge, skills, attitudes); 2. the social context in
which the clinician works (e.g. patients, colleagues, au-
thorities); and 3. the organizational context (e.g. resources,
organizational climate) [6]. Failure to implement recom-
mendations can result in inappropriate, unnecessary or
harmful healthcare provision [7]. For youth depression, as
well as endeavoring to ensure recovery, the recommenda-
tions are critical in addressing safety concerns about anti-
depressant medication for this age group.
US research based on data submitted to the Food and
Drug Administration (FDA) has shown those up to the
age of 25 treated with antidepressant medication are more
likely to experience an increase in suicidal ideation andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Hetrick et al. BMC Health Services Research 2012, 12:178 Page 2 of 7
http://www.biomedcentral.com/1472-6963/12/178suicide attempts [8-10] resulting in controversy about
what constitutes optimal treatment for youth depression
[11-14]. We sought to identify the impact of this on clini-
cians’ implementation of guideline recommendations in a
public youth mental health service. In an initial study [15],
we identified potential barriers to implementing these
recommendations, including clinician beliefs that the
recommendations were not relevant to young people pre-
senting to the service, due to the severity and complexity
of presentations with clinicians believing medication was
warranted earlier than recommended, and that delivery of
psychotherapy was difficult. Barriers also existed to under-
taking regular monitoring of young people prescribed
medication, including a lack of doctors, a perceived lack of
expertise of case managers, and lack of time for systematic
monitoring resulting in reliance on a passive approach,
dependent on client spontaneous report [15]. Our results
were consistent with a US study concluding clinicians
wanted more emphasis on the therapeutic relationship,
and greater flexibility in implementing guideline recom-
mendations [16].
In this second study, we sought to examine actual
practice. On the basis of the findings above we hypothe-
sised that ‘real-world’ practice, while broadly in line with
guideline recommendations, might require improve-
ments in some areas. At the time of the study, the Aus-
tralian guidelines did not exist, therefore, we chose the
U.K. NICE guidelines [3] as exemplars of the recommen-
dations made in guidelines internationally.
We focused on four key behaviours recommended in
the NICE guideline[3]:
1. That the clinician establishes depressive disorder
symptom severity
2. That young people are offered medication if the
(moderate to severe) depression is unresponsive after
receiving four to six sessions of psychological therapy
3. That the first medication offered is fluoxetine
4. That careful monitoring of emergent suicidality and
general progress (interpreted in this study as
improvement of depression symptoms) take place
once fluoxetine is prescribed, operationalized as
once a week for four weeks.
The purpose of the research was to investigate these
specific behaviours with the aim to ascertain gaps be-
tween guideline recommendations and clinical practice
in the management of young people with depression in a
public mental health setting.
Methods
Setting and sample
In Australia, public mental health services provide free
mental health care for those with serious mentaldisorders. Our study took place at Orygen Youth Health
(OYH); a public mental health service for young people
aged 15-24 living in the northwestern metropolitan area
of Melbourne, Australia. OYH receives referrals from
primary services (e.g. general practitioners) and second-
ary services (e.g. pediatricians), although any referrals
are considered, including direct referrals from young
people, their caregivers, or places such as education set-
tings. The Youth Access Team (YAT) receives these
referrals, undertakes assessment and allocates young
people to a clinical program. The clinical programs
included the Personal Assessment and Crisis Evaluation
(PACE) team for those at high risk of developing a
psychotic disorder, the Early Psychosis Prevention and
Intervention Clinic (EPPIC) for first episode psychosis,
the Youth Mood Clinic (YMC) for moderate/severe de-
pression, the Helping Young People Early (HYPE) clinic
for emerging borderline personality disorder, the Inten-
sive Mobile Youth Outreach Service (IMYOS) for out-
reach treatment to enhance engagement, and the service
specific Inpatient Unit (IPU).
Sample
The study aimed to collect data from 150 consecutive
clients who met the following inclusion criteria: they
entered a clinical program at OYH for the first time be-
tween 1 April and 30 September 2007; they had a diag-
nosis of depressive disorder (DD), or had been
prescribed antidepressants or antipsychotics (the latter
included to ensure prescription of this class of medica-
tion for depressive disorder was captured) at least once
in the first six months from the date of first presentation
at OYH (the ‘audit period’).
DD was defined as Depressive Disorder NOS, Major
Depressive Disorder Single or Recurrent of any level of
severity, with or without psychotic features, or where
‘Depressive Disorder’ or ‘MDE’ or ‘Depression’ or ‘De-
pression Symptom’s’ was recorded in the medical file.
This was established after reviewing the entire medical
file.
Of the 221 clients entering an OYH clinical program
between 1 April and 30 September 2007, 146 met the in-
clusion criteria. Of these, 121 (83%) had a diagnosis of
depression during the audit period. Their mean age was
18.8 years (SD 2.9); 33.1% were male; none identified as
indigenous, although four had ‘unknown’ ethnicity. The
eligible clients had been with the assessment team
(YAT) or inpatient unit on average 32.0 (SD 21.1) days
(range 4 to 141) before allocation to a clinical program.
The diagnosis or indication of a diagnosis of depression
was recorded in 15 different ways at baseline assessment,
the most common notation being “MDE or major de-
pressive episode” (62%) with DSM-IV severity specifiers
seldom used (<25%). Only 10 of the 121 clients with a
Figure 1 Histogram of the number of days to first anti-
depressant prescription (depressed, anti-depressant naïve
patients).
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nosis of depression alone. The remainder had at least
one additional diagnosis with these diagnoses classified
into 20 categories.
The local ethics review committee approved the study
(Melbourne Health Research and Ethics Committee;
reference number 2008.18).
Data collection
A data collection form or ‘audit’ form was designed spe-
cifically for the study, which included extensive instruc-
tions on coding for each item, and additional
information describing codes for medication and diagno-
sis. Approximately 20% of the files were audited by visit-
ing psychiatric registrars (n = 4), who were given
extensive training in use of the audit form by the Princi-
pal author (SH) who audited the majority of files. A pro-
ject specific database was designed and a research
assistant entered all of the data from the audit forms.
Statistical analysis
Descriptive statistics including means, standard devia-
tions and frequency counts were used to describe the
timing and type of interventions used, the medications
prescribed and the frequency of monitoring of symp-
toms and adverse outcomes. Where relevant, data ana-
lysis was undertaken according to age i.e. those aged 18
years and under and those aged over 18, given the NICE
guidelines [3] apply to those 18 years and under. Minitab
(version 16) and Microsoft Excel were used to manipu-
late data files and to obtain the descriptive statistics.
Results
Establishing the severity of depression
Only 61 out of 121 (50.4%) patients with a diagnosis of
depression had a baseline assessment of the severity of
depression recorded using the service’s mandated tools
(Health of Nations Outcome Scales; a UK scale measur-
ing the health and social functioning of people with se-
vere mental illness [17]): HoNOS (item 7 on this scale
rates “problems with depressed mood” for >18 years) or
HoNOSCA (item 9 on this scale rates “problems with
emotional or related symptoms” for <18 years). When
measurement of depression severity via other means,
largely interview based clinical assessment, was taken
into account, a total of 104 (86%) clients had severity
recorded.
Timing of prescription of an antidepressant
Thirty-two (26.4%) young people diagnosed with depres-
sion during the audit period were already on an anti-
depressant at the time of entry to OYH. Of those who
were antidepressant naïve on entry, 26 (29.2%) did not
receive any medication during the audit period; 55(61.8%) were prescribed one or more antidepressants
during the audit period with 20 receiving an antidepres-
sant alone.
The earliest first prescription date was identified for
each of the 55 antidepressant naïve clients prescribed an
antidepressant during the audit period. The mean number
of days to the first prescription of an antidepressant was
27 (SD 29.6); the majority (74.5%; n = 41) receiving this
prescription in less than 42 days (see Figure 1) or 6 weeks,
about the time it takes to deliver “four to six sessions” of
psychological therapy as recommended by the guidelines.
Our earlier work [15] highlighted clinicians’ concerns
that severe depression warranted earlier initiation of
medication; therefore, we investigated the severity of de-
pression in those who received a prescription for an
antidepressant in less than six weeks of entry to OYH
(N= 41). Only 33 had a baseline assessment of depres-
sion severity recorded (including HoNOS, HoNOSCA or
interview based clinical assessment). Of these, 6% had
‘no problem’, 3% had mild depression, 51.5% had moder-
ate depression and 39.4% had severe depression.
Type of medications prescribed
The first antidepressant prescribed for the 55 antidepres-
sant naïve clients (on entry to OYH) who received a pre-
scription for an antidepressant during the audit period
was fluoxetine in 70.9% of cases (92% for those under 18
years of age and 53.3% for those over 18 years of age)
(see Table 1).
Monitoring of emergent suicidality and general progress
As a proxy of the guideline recommendation that young
people prescribed medication should be ‘carefully moni-
tored’ (operationalised as ‘weekly. . .for the first 4 weeks’
(pg.127) [3]), an analysis of how many young people
diagnosed with depression and treated with an anti-
depressant during the audit period (N= 83) had at least
Table 1 Type of first antidepressants for antidepressant naïve patients with a depression diagnosis; overall and by age
group
All N= 15 18 years or younger N=25 Over 18 Years N= 18
Medication class Number prescribed this medication Number prescribed this medication Number prescribed this medication
Citalopram 5 (9.1%) 2 (8.0%) 3 (10.0%)
Escitalopram 3 (5.5%) 0 (0.0%) 3 (10.0%)
Fluoxetine 39 (70.9%) 23 (92.0%) 16 (53.3%)
Paroxetine 2 (3.6%) 0 (0.0%) 2 (6.7%)
Sertraline 2 (3.6%) 0 (0.0%) 2 (6.7%)
Mirtazapine 4 (7.3%) 0 (0.0%) 4 (13.5%)
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any clinician within the first four weeks of prescription
of medication was undertaken. Follow-up contact is a
contact on any day after the day of prescription of the
antidepressant. Contact could be with a doctor, the in-
take/assessment team (YAT) or an Outpatient Case
Manager (OCM), or any combination of these. Contacts
with a doctor, for example, were counted as the contacts
with a doctor alone or the contacts made in combination
with anyone else. Table 2 shows the numbers who had
at least one follow-up phone contact each week and at
least one follow-up face-to-face contact each week for
four weeks.
Twenty-five (30%) of 83 patients with a diagnosis of
depression and receiving anti-depressants at some point
during the audit period had a suicide ideation/risk as-
sessment at least once a week for four weeks after the
first prescription of anti-depressant.
The outcome of the assessment on two questions was
considered:
 Any current suicidal ideation/thoughts/intent?
 Any suicide attempt since last contact or current?
Of the 25 patients with four weekly assessments, 10
had a clear answer to the question “Any current suicidal
ideation/thoughts/intent?” in every one of the four
weeks; for 15 it was unclear from the medical file and
therefore recorded as such in the audit form. Only one
of the 25 had a clear answer to the question “AnyTable 2 Number of patients with one or more successful
contacts each week in the four-week follow up after
prescription of anti-depressants
Any Contact Phone Face-To-Face
Doctor 1 (1.2%) 0 (0.0%) 1 (1.2%)
OCM 11 (13.3%) 0 (0.0%) 9 (10.8%)
YAT 12 (14.5%) 5 (6.0%) 1 (1.2%)
Any of the above 39 (47.0%) 6 (7.2%) 23 (27.7%)
OCM: Outpatient Case Manager; YAT: Youth Assessment Team.suicide attempt since last contact or current?” in every
one of the four weeks.
Twenty-nine (35%) of the 83 were assessed for depres-
sion severity at least once per week in the four-week
period. Only one of these patients was assessed with a
recognized scale.Discussion
Principal findings
As anticipated, based on prior analysis of barriers to
implementing youth depression guidelines [15], while
practice is broadly in line with guideline recommenda-
tions, significant improvements are required in some areas
to ensure recommendations are followed appropriately.
First, the current study shows less than 100% concord-
ance with the assessment and recording of depression
severity, despite treatment recommendations being
largely determined by severity. Depression severity is
often simply gauged by clinical judgement using DSM/
ICD; however, this was seldom done and even in the
context of a mandated tool (though not a specific
depression scale), the lack of uniformity in establishing
severity striking. In no case was there evidence that a
depression scale measure was used.
Second, the majority of young people who were anti-
depressant naïve on entry to the service did not appear
to have an adequate trial of psychological therapy before
prescription of an antidepressant. Ours [15] and other
research [16] has highlighted clinicians’ concerns about
the applicability of evidence for those with severe
presentations. The US primary care guidelines (Recom-
mendation 3, pg 1319) [1], practice parameters of the
AACAP (Recommendation 9, pg 1511) [2] and new
Australian guidelines include a caveat allowing earlier
prescription of medication in this case (Recommenda-
tion 5: pg 55) [4]. However, the early prescription
demonstrated in the current study was not entirely
accounted for by the severity of depression.
It could be that medication was prescribed earlier for
young people who declined to engage in psychological
therapy. Our previous work has highlighted difficulties
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tions in psychotherapy. Again the US primary care guide-
lines (Recommendation 3, pg 1319) [1] and practice
parameters of the AACAP (Recommendation 9, pg 1511)
[2], the Australian guidelines (Recommendation 5, pg 55)
[4] as well as the NICE guidelines (Recommendation
7.10.1.3, pg 127) [3] allow provision for medication in this
case. This is somewhat paradoxical given the need for close
monitoring in the case of medication prescription and the
significant gaps between recommendations about monitor-
ing and actual practice highlighted in this research.
Third, fluoxetine was the first medication prescribed
for 92% for those 18 years and under, and 53.3% for
those over 18 years. This is an encouraging result for
those under 18 and suggests that unambiguously stated
and potentially less complex recommendations are more
likely to be carried out. The result for those over 18 was
not unexpected given the audit was undertaken before
the Australian guidelines [4], which include ‘good prac-
tice points’ recommending extrapolation of evidence for
those up to the age of 25, were released. These good
practice points are based on the FDA data showing an
increased risk of suicide related behaviours after pre-
scription of an antidepressant for those up to the age of
25 [18].
Finally, the Nice guidelines recommend “careful moni-
toring of adverse drug reactions, as well as for reviewing
mental state and general progress; for example, weekly
contact with the child or young person and their parent
(s) or carer(s) for the first 4 weeks of treatment” (Recom-
mendation 7.10.1.3 pg 127) for those initiated on an
antidepressant. Our results show monitoring was under-
taken far less frequently than recommended and was not
done in a systematic nor precise way. This is consistent
with previous US research [19]. Our previous work
regarding clinicians’ perceived lack of expertise and time
to undertake systematic monitoring, particularly of
medication induced adverse side effects [15]. Together
with research that has highlighted that a reliance on
spontaneous report of side effects does not sufficiently
identify all those at risk of suicide [20], the current
results provide further impetus for services to invest in
systems that allow regular collection of standardized
information about adverse effects, emergent suicidality
and resolution of depression symptoms, for example, an
easily accessible online tool that incorporates all
elements requiring monitoring.Strengths and weaknesses of the study
We did not formally assess inter-rater reliability; rather
we relied on a high level of detailed instruction in the
audit form and intensive training. The Principal author
also undertook the majority of the audit.Our results are based on medical files records rather
than observation of what actually took place. This lim-
ited the set of behaviours that we could investigate; for
example, it was not practical to assess the type of psy-
chotherapy e.g. CBT or IPT being conducted as the as-
sessment of this from case notes was felt to be highly
inaccurate.
This is the first study to our knowledge assessing this
range of key clinician behaviours in a public youth men-
tal health service relative to guideline recommendations
for the treatment of depression in young people. Some
research has been undertaken to assess the gaps between
guideline recommendations and clinical practice
[19,21,22], but each focus on only one or two recommen-
dations. Our results are consistent with research on guide-
line implementation and the quality of depression care in
adults. Adherence to guideline recommendations for adult
depression is generally low in primary care e.g. [23-25]
even when interventions aiming to improve evidence
based care are implemented e.g. [26-28]. Of the few stud-
ies that have been undertaken in adult mental health
specialist settings, adherence is better. For example in a
national survey in the US, while appropriate care (defined
as the respondent receiving medication or counseling
consistent with guidelines) was only received by 19% of
those who visited primary care providers, 90% of those
visiting mental health specialists received appropriate care
[24]. One study looking at more specific indicators of
guideline adherence by psychiatrists in private practice
showed targeted training about providing guideline
concordant care resulted in patients receiving more medi-
cation [29]. Another study in psychiatric outpatient
services showed adherence with all of a range of indicators
of guideline adherence was seen in up to 55% of cases. Of
note was the very low adherence to recommendations
regarding routine outcome monitoring in the therapeutic
phase [30].
Conclusion
The publication and dissemination of guidelines is not
sufficient to ensure that evidence based recommenda-
tions are incorporated into every day clinical practice.
This research has highlighted some areas that require
specific improvement, including the systematic assess-
ment and recording of depressive disorder symptom se-
verity to ensure appropriate treatment planning. These
findings are consistent with other research that has been
undertaken and is likely to be applicable to youth public
mental health services more broadly. Practice system
tools are useful for ensuring the uptake of evidence into
practice [31]. For young people with depression, tools
that allow for the ongoing monitoring of depression
symptoms, adverse side effects - in particular treatment
emergent suicide related behaviours - are critical given
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depressant medication [10,32]. For young people who
decline to engage in psychological therapy but neverthe-
less require medication, ongoing monitoring is critical.
There is room for improvement with regard to ensuring
an adequate trial of psychological therapy before medi-
cation is initiated, highlighting the need to establish the
most effective elements of guideline recommended
psychotherapy for young people and develop innovative
ways to deliver these in ways that are engaging and
acceptable to young people.
Finally, identifying and understanding the evidence-
practice gaps, as well as barriers to implementing
evidence allows the development of targeted strategies
to ensure the uptake of evidence based guideline recom-
mendations into everyday practice.
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